Add to Favourites
To login click here
Leash Biosciences, an AI/ML-native biotechnology company, has completed a $9.3 million seed financing round to advance its mission of revolutionizing medicinal chemistry through modern computational methods and massive biological data collection. The company aims to develop a foundational and generalizable machine learning model of medicinal chemistry that can accurately predict small molecule drug candidates for any protein in silico. Leash has physically generated over 17 billion high-quality protein-chemical interaction measurements and plans to screen 500+ protein targets against millions of machine learning-designed chemicals by 2025.